Get the Stockscreener App
1.59
1.27%
0.02
After Hours:
1.59
Caribou Biosciences Inc stock is traded at $1.59, with a volume of 731.48K.
It is up +1.27% in the last 24 hours and down -5.36% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
See More
Previous Close:
$1.57
Open:
$1.6
24h Volume:
731.48K
Relative Volume:
0.37
Market Cap:
$157.70M
Revenue:
$11.16M
Net Income/Loss:
$-148.13M
P/E Ratio:
-1.0009
EPS:
-1.5885
Net Cash Flow:
$-112.35M
1W Performance:
-1.85%
1M Performance:
-5.36%
6M Performance:
+2.58%
1Y Performance:
-30.26%
1-Day Range:
$1.58
$1.65
1-Week Range:
$1.57
$1.725
52-Week Range:
$1.38
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.59 | 155.71M | 11.16M | -148.13M | -112.35M | -1.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
CRBU|Caribou Biosciences Inc|Price:1.585|Chg%:+0.015 - TradingKey
Caribou Biosciences Inc (CRBU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Caribou Biosciences Inc (CRBU) Cash Flow - TradingKey
BlackRock (NYSE: BLK) reports 7.2% beneficial stake in Caribou Biosciences (CRBU) - Stock Titan
Caribou Biosciences Inc (CRBU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Caribou Biosciences Inc (CRBU) Balance Sheet - TradingKey
Caribou Biosciences Inc (CRBU) Income Statement - TradingKey
Caribou Biosciences Inc (CRBU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Caribou Biosciences, Inc. Revenue Breakdown – NASDAQ:CRBU - TradingView
Caribou Biosciences Inc (CRBU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CRBU|Caribou Biosciences Inc|Price:1.570|Chg%:-0.060 - TradingKey
Caribou Biosciences Inc (CRBU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enterprise value to EBIT forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences Inc (CRBU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Price to earnings forward of Caribou Biosciences, Inc. – NASDAQ:CRBU - TradingView
Caribou Biosciences secures e-poster spot for ANTLER abstract at PPLC 2026 - Traders Union
Caribou Biosciences Inc (CRBU) Institutional Confidence - TradingKey
Are medical stocks lagging Caribou Biosciences (CRBU) this year? - MSN
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year? - Yahoo Finance
Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart.com
The Gross Law Firm Notifies Shareholders of Caribou Biosciences, - GuruFocus
Caribou Biosciences stock holds focus on CRISPR therapies - ad-hoc-news.de
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Index - marketscreener.com
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Investing News Network
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Microcap Value Benchmark Index - marketscreener.com
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Value Benchmark - marketscreener.com
Caribou CEO set for fireside chat at cell therapy conference June 30 - Stock Titan
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire Inc.
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell Microcap Index - marketscreener.com
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
CRBUCaribou Biosciences Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences - The National Law Review
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Small Cap Completeness Index - marketscreener.com
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirt - The National Law Review
Caribou Biosciences, Inc. Actuals & Estimates (NASDAQ:CRBU) - TradingView
CRBU Forecast — Price Target — Prediction for 2027 - TradingView
Caribou Biosciences StockLong-term CRISPR strategy in focus - AD HOC NEWS
Caribou Biosciences Shareholders Decide Key Governance Matters - TipRanks
Caribou Biosciences (NASDAQ: CRBU) holders reject officer exculpation - Stock Titan
Caribou Biosciences Inc (CRBU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CRBU Q1 2026 Earnings: EPS Beat Offers Little Reprieve as Stock SlipsTech Earnings Analysis - newsline.com
Caribou Biosciences Inc (CRBU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy - Investing.com
Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses - CRISPR Medicine News
Investors who lost money on Caribou Biosciences, Inc.(CRBU) shou - GuruFocus
Longer-term CB-011 results unveiled by Caribou Biosciences at EHA2026 - Traders Union
Caribou Biosciences (CRBU) Slides 3.92%, Nears Critical Support at $1.51Catalyst Driven Stocks - newsline.com
Caribou Biosciences, Inc. (CRBU) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA - Traders Union
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):